Autism and Neuroinflammation
Neuroinflammation — chronic inflammation within the brain and central nervous system — is one of the most consistently documented biological findings in autism research. Studies repeatedly identify activated microglia (the brain's resident immune cells), elevated inflammatory markers in cerebrospinal fluid, and persistent neuroinflammatory processes across post-mortem and PET imaging studies. At Autism Stem Care, addressing neuroinflammation is a central pillar of our regenerative medicine approach.
What Neuroinflammation Actually Is
Neuroinflammation is activation of the brain's innate immune system — primarily microglia and astrocytes. Short-term activation is normal and protective. Chronic activation is harmful: it can impair synaptic development and pruning, disrupt neural connectivity, affect neurotransmitter production and signaling, damage developing neural tissue, and interfere with the brain's normal maturation. In autism, this chronic activation has been documented across multiple research methodologies and is one of the strongest biological signatures we can target.
How MSC Therapy Targets Brain Inflammation
Mesenchymal stem cells are powerful anti-inflammatory agents with a particular affinity for inflamed tissues. When administered intravenously or intrathecally, MSCs can migrate toward areas of inflammation and release anti-inflammatory cytokines and growth factors, modulate microglial activation from a pro-inflammatory toward a protective phenotype, promote neurotrophic factor release that supports neural repair, reduce oxidative stress in neural tissue, and support blood-brain barrier integrity.
Why Intrathecal Administration Matters Here
Intrathecal administration delivers stem cells directly into the cerebrospinal fluid, bypassing the blood-brain barrier and providing more direct CNS access than IV administration. For children with strong neuroinflammatory features — regression history, behavioral instability during illness, severe sensory dysregulation — intrathecal delivery may offer meaningful advantages. Whether it is appropriate is a medical decision made during the eligibility review.
The Role of Exosomes in Neuroinflammation Protocols
Exosomes — nano-scale vesicles released by stem cells — carry concentrated anti-inflammatory and neurotrophic signaling molecules. They cross biological barriers more easily than whole cells and can be delivered intravenously or intranasally (intranasal delivery is exclusive to exosomes; whole stem cells are never administered intranasally because of size). Exosomes are frequently combined with MSC therapy in neuroinflammation-focused protocols to amplify and prolong anti-inflammatory effects.
Clinical Clues That Neuroinflammation Is Significant
We pay close attention to certain clinical patterns: regression history (especially around 18–30 months), worsening of symptoms during minor infections, behavioral regression after vaccinations or fevers, severe sensory dysregulation, sleep disturbances that don't respond to standard sleep interventions, and elevated systemic inflammatory markers when measured. These are not diagnostic alone, but together they help inform protocol design.
What to Expect From a Neuroinflammation-Focused Protocol
Protocols typically combine MSC therapy (often with intrathecal administration), exosome therapy (sometimes including intranasal delivery), and supportive antioxidant IV therapies. The visit is paced over 5–7 days with daily monitoring. Follow-up explicitly tracks inflammation-relevant outcomes — illness frequency, behavioral stability during stress, sleep quality, and developmental observations.
Signs and Symptoms
- Regression of previously acquired skills
- Worsening of symptoms during illness
- Chronic irritability without clear cause
- Sleep disturbances
- Cognitive and attention difficulties
- Sensory processing disruptions
How We Help
Neuroinflammation is a primary target of our regenerative protocols. We use MSC therapy (often intrathecal), exosome treatments (including intranasal where appropriate), and supportive antioxidant care to specifically reduce brain inflammation and support neural repair.
FAQ
How do you know if my child has neuroinflammation?
Direct measurement requires advanced imaging not routinely available. We assess clinical history (regression, illness sensitivity), symptom patterns, blood inflammatory markers where measured, and response patterns to identify children who may benefit from anti-inflammatory regenerative approaches.
Is intrathecal administration better for neuroinflammation?
For children with strong neuroinflammatory features, intrathecal delivery may offer meaningful advantages by providing direct CNS access. The decision is medical, made during your child's eligibility review.
Why are exosomes given intranasally and not stem cells?
Exosomes are nano-scale and small enough to traverse the nasal-brain pathway. Whole stem cells are far too large and are never administered intranasally — only exosomes use this route.
Can MSC therapy reverse damage already done?
Regenerative medicine cannot undo all prior neurological changes, but it may reduce ongoing inflammation, support repair, and improve the brain's capacity for plasticity going forward.
How many sessions are typically needed?
Most protocols start with a single comprehensive visit and reassess at 3–6 months. Some children benefit from a second session; others do not need one. Decisions are made based on follow-up data, not a fixed schedule.
Will my child need to stop anti-inflammatory medications before treatment?
Generally no, but specific medications (especially immunosuppressants) are reviewed individually. Our team coordinates with your prescribing physicians on any peri-treatment adjustments.
Related: Intrathecal Stem Cell Administration | Umbilical Cord Mesenchymal Stem Cells | Exosome Therapy